Effect of Dapagliflozin in Type 2 Diabetic Patients with Hyperfiltration: a Randomized Controlled Study

The Effect of Dapagliflozin in Delaying Renal Progression in Type 2 Diabetic Patients with Hyperfiltration: a Randomized Controlled Study

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000037196

Enrollment

Unknown

Registered

2020-08-27

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetic Patients With Hyperfiltration

Interventions

Experimental: Intervention (Dapagliflozin):Dapagliflozin 5mg tablet taken by mouth once daily for 2 years

Placebo Comparator: Control (Placebo):Placebo tablet taken by mouth once daily for 2 years

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years, no gender limit; 2. Clinically diagnosed as type 2 diabetes; 3. eGFR >= 120 mL/min (according to CKD-EPI formula); 4. HbA1c 7.0-10% at the time of screening; 5. BP 100/70mmHg, no microalbuminuria; 6. Sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Allergic to dapagliflozin tablets; 2. Pregnancy or breastfeeding; 3. Severe ketoacidosis occurred within 1 month before screening; 4. There was uncured urinary tract infection at the time of screening.

Design outcomes

Primary

Measure	Time frame
Microalbuminuria;	—

Secondary

Measure	Time frame
Glomerular filtration rate;Cardiovascular disease events;	—

Countries

China

Contacts

Public ContactMan Yang

Shanghai General Hospital

yangman5113@126.com+86 13611722486

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026